Citace:New medicine to protect honey bees against Varroa mites

VarroMed recommended for marketing authorisation

At its October meeting, the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) recommended the granting of a marketing authorisation in the European Union (EU) for VarroMed (oxalic acid dihydrate / formic acid).
...
The CVMP opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation.

Notes
1. The applicant for this veterinary medicinal product is BeeVital GmbH.

Citace:VarroMed is intended to be used as part of an integrated Varroa control programme, which includes not only treatment with medicines but also non-chemical techniques like queen trapping or drone brood removal. It can be used either as a single-dose treatment during the broodless period (winter treatment) or in the presence of brood (spring or autumn), which will usually require repeated treatments.

Citace:The 1st ever Bee Medicine with EU-wide approval: Ready-to-use for Spring/Autumn/Winter treatment

Citace:Due to the nature of the ingredients VARROMED does not pose any risks to honey production. In fact, this is reflected in the zero-day-withdrawal period of VARROMED approved by the EMA.

Citace:The introduction to the markets is scheduled for beginning of 2017.

Citace: Druhý seznam uvádí veterinární léčivé přípravky registrované centralizovaným postupem Společenství, pro které vydala rozhodnutí o registraci Evropská komise. Toto rozhodnutí platí na území všech členských států ES.